oral sel. IDO1 dioxygenase inhibitor
100 mg QD, in I/O combo studies for cancer
acts on apo-IDO1 displacing heme co-factor
Mol. Cancer Ther., Dec. 9, 2020
BMS, Princeton, NJ / Flexus, San Carlos, CA
Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor